T-Curx obtained Swissmedic approval for a first-in-human Phase I study of TCX-001, a Siglec-6-targeted nonviral CAR T program. The trial will open in Switzerland with plans to expand to Germany via an EMA submission. Investigators will enroll adults with relapsed or refractory AML and CLL, including patients not eligible for stem cell transplantation. The regulatory clearance signals progress for nonviral CAR approaches aimed at broadening applicability while controlling manufacturing and safety constraints typically associated with viral delivery.